Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
University Medical Center Nijmegen
Eligible women will choose for the innovative or standard risk-reducing option themselves.
Age
25–45
Sex
FEMALE
Healthy volunteers
Not accepted
You may be eligible if
Premenopausal women with a documented BRCA1 and/or BRCA2 germline mutation
Age 25-40 years for BRCA1 mutation carriers, 25-45 years for BRCA2
Childbearing completed
Presence of at least one fallopian tube
Participants may have a personal history of non-ovarian malignancy
You may not be if
Postmenopausal status (natural menopause or due to (cancer) treatment)
Wish for second stage oophorectomy within two years after salpingectomy (if clear at enrollment)
Legally incapable
Prior bilateral salpingectomy
A personal history of ovarian, fallopian tube or peritoneal cancer
Evidence of malignant disease at enrollment
Treatment for malignant disease at enrollment
Inability to read or speak Dutch
BRCA mutation carriers who opt for salpingectomy but who do not want to postpone the oophorectomy beyond the guideline age will undergo similar follow-up but do not contribute to the 510 inclusions we need
Clareo Health | Early Salpingectomy (Tubectomy) With Delayed Oophorectomy in BRCA1/2 Gene Mutation Carriers
